section name header

Pronunciation

for-MO-te-role

Classifications

Therapeutic Classification: bronchodilators

Pharmacologic Classification: adrenergics

Indications

REMS


Action

  • Produces accumulation of cyclic adenosine monophosphate (cAMP) at beta-adrenergic receptors, resulting in relaxation of airway smooth muscle.
  • Relatively specific for beta2 (pulmonary) receptors.
Therapeutic effects:
  • Bronchodilation.

Pharmacokinetics

Absorption: Following inhalation, majority of inhaled drug is swallowed and absorbed.

Distribution: Unknown.

Metabolism/Excretion: Mostly metabolized by the liver; 10–18% excreted unchanged in urine.

Half-Life: 10 hr.

Time/Action Profile

(bronchodilation)

ROUTEONSETPEAKDURATION
Inhaln15 min1–3 hr12 hr



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: angina, arrhythmia, hypertension, hypotension, palpitations, tachycardia

Derm: rash

F and E: hypokalemia

GI: dry mouth, nausea

Metab: hyperglycemia, metabolic acidosis

MS: muscle cramps

Neuro: dizziness, fatigue, headache, insomnia, malaise, nervousness, tremor

Resp: PARADOXICAL BRONCHOSPASM

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Perforomist

Canadian Brand Names

Oxeze Turbuhaler